Role of RGM coreceptors in bone morphogenetic protein signaling by Halbrooks, Peter J et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Journal of Molecular Signaling
Open Access Research article
Role of RGM coreceptors in bone morphogenetic protein signaling
Peter J Halbrooks1, Ru Ding2,  J o h nMW o z n e y 2 and Gerard Bain*2
Address: 1Quality Control Technical Services Laboratory, Genzyme Corporation, Framingham MA, 01701, USA and 2Women's Health and 
Musculoskeletal Biology, Wyeth Discovery Research, Cambridge, MA, 02140, USA
Email: Peter J Halbrooks - Peter.Halbrooks@genzyme.com; Ru Ding - RDing@wyeth.com; John M Wozney - JWozney@wyeth.com; 
Gerard Bain* - GBain@wyeth.com
* Corresponding author    
Abstract
Background: The repulsive guidance molecule (RGM) proteins, originally discovered for their
roles in neuronal development, have been recently identified as co-receptors in the bone
morphogenetic protein (BMP) signaling pathway. BMPs are members of the TGFβ superfamily of
signaling cytokines, and serve to regulate many aspects of cellular growth and differentiation.
Results: Here, we investigate whether RGMa, RGMb, and RGMc play required roles in BMP and
TGFβ signaling in the mouse myoblast C2C12 cell line. These cells are responsive to BMPs and are
frequently used to study BMP/TGFβ signaling pathways. Using siRNA reagents to specifically knock
down each RGM protein, we show that the RGM co-receptors are required for significant BMP
signaling as reported by two cell-based BMP activity assays: endogenous alkaline phosphatase
activity and a luciferase-based BMP reporter assay. Similar cell-based assays using a TGFβ-induced
luciferase reporter show that the RGM co-receptors are not required for TGFβ signaling. The
binding interaction of each RGM co-receptor to each of BMP2 and BMP12 is observed and
quantified, and equilibrium dissociation constants in the low nanomolar range are reported.
Conclusion: Our results demonstrate that the RGMs play a significant role in BMP signaling and
reveal that these molecules cannot functionally compensate for one another.
Background
The transforming growth factor β (TGFβ) superfamily of
ligands, which includes the TGFβ proteins, bone morpho-
genetic proteins (BMPs), growth and differentiation fac-
tors (GDFs), and others, plays a key role in regulating cell
proliferation, differentiation, migration, and apoptosis in
a diverse set of developmental and physiological path-
ways. These secreted signaling proteins exert crucial func-
tions at several stages of development and are essential for
tissue repair and maintenance in the adult [1-4]. The
pathogenesis in a host of diseases, including cancer, oste-
oporosis, and fibrosis, has been attributed to disregulated
TGFβ superfamily function [5]. The BMPs, the largest sub-
group within the TGFβ superfamily, participate in the
development of nearly all organs and play a critical role in
the formation and repair of bone [6,7]. The TGFβ s are
known to play important roles in cellular proliferation
and differentiation, inflammation and tissue repair, and
host immunity [4,8,9].
TGFβ family ligands mediate their effects by binding to
specific pairs of membrane bound type I and type II ser-
ine/threonine kinase receptors, leading to the activation
of distinct intracellular Smad pathways. These phosphor-
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ylated receptor-regulated Smads are translocated from the
cytoplasm to the nucleus where they function to assist in
specific gene activation. In general, ligands in the TGFβ
superfamily activate either of two Smad branches. The
BMPs activate Smads 1/5/8, while the TGFβ/Activins acti-
vate Smads 2/3, although recent reports have demon-
strated that there can be rare exceptions to this rule [10].
A multitude of regulatory mechanisms are required for
these functions, in order to ensure that this powerful net-
work of signaling molecules functions with specific distri-
bution and activation. Such mechanisms include ligand-
specific extracellular antagonists [7], molecular recogni-
tion of the type I and type II cellular receptors [11], and
the presence of cell surface pseudoreceptors [12]. An
emerging, yet important, regulatory mechanism for some
TGFβ superfamily members is the presence of co-receptors
(also called accessory or type III receptors) which promote
or inhibit ligand binding [13-15]. Two examples are that
of betaglycan, which plays an essential role in TGFβ sign-
aling [16], and endoglin, which has been implicated in
Alk1 ligand signaling [17]. An additional co-receptor,
cripto, has been shown as an essential cofactor in Nodal
signaling [18]. Co-receptors do not appear to have any
intrinsic signaling activity, but rather serve to regulate
TGFβ access to the signaling receptors [4].
Recently, three members of the repulsive guidance mole-
cule (RGM) family have been implicated in the BMP sign-
aling pathway [19-22]. RGMa, RGMb (DRAGON), and
RGMc (hemojuvelin/HFE2) have all been shown to
enhance cellular responses to BMP signals, and also to
bind BMP2 ligand. In addition to sharing significant
sequence homology (50–60% amino acid identity,
including a shared partial von Willebrand factor type D
domain), all three RGM molecules are glycosylphosphati-
dylinositol (GPI)-anchored membrane proteins [19,23-
25]. The RGMs were first implicated in both axonal guid-
ance and neural tube closure [23]; more recently, muta-
tions in the gene encoding RGMc have been identified as
the leading cause of juvenile hemochromatosis, a condi-
tion of iron-overload [26,27]. RGMa and RGMb are
expressed prominently in the nervous system [25]. Signif-
icant expression of RGMc has been observed in the liver,
heart, and skeletal muscle in humans, but is also widely
expressed in a host of other tissues, including brain [28].
Here, we further examine the role of the RGMs as co-
receptors for BMP2. In addition, because it has recently
been shown that BMP12 can signal through the same
pathway as BMP2 [29], we have investigated the function
of the RGMs in regulating BMP12 signaling as well. Using
two separate functional readouts (BMP-responsive
reporter gene and endogenous alkaline phosphatase
enzyme activity assays), it is shown that siRNA-mediated
knockdown of RGMa or RGMc almost completely inhibits
BMP2 and BMP12 signaling. While not as dramatic, the
specific targeting of RGMb is also shown to significantly
impact the BMP induced response. Knockdown of the
RGMs failed to affect TGFβ responsiveness in the CAGA-
luc reporter assay, demonstrating that the RGMs are
important for BMP but not TGFβ responsiveness. Addi-
tionally, quantitative binding experiments using surface
plasmon resonance allowed us to assess binding affinities
between the BMP ligands and RGMa, RGMb, or RGMc.
Taken together, these data confirm the role for the RGMs
as co-receptors in BMP2 and BMP12 signaling, and that
selective knockdown of the RGMs results in dramatic
reduction of the BMP responses.
Results
siRNA mediated mRNA knockdown
To validate the specificity and efficacy of mRNA knock-
down by the siRNA duplexes, we performed real-time
quantitative RT-PCR using total RNA extracted from dif-
ferentially treated cells to define the expression pattern of
RGMa, RGMb, and RGMc. For each co-receptor, siRNA
duplexes targeting four independent nucleotide
sequences were analyzed individually to help control for
unintended off-target effects. The results (Figure 1) dem-
onstrate that all 3 RGMs are expressed in C2C12 cells and
confirm that each set of siRNA duplexes specifically sup-
presses mRNA expression of its intended co-receptor,
while mRNA levels of the other co-receptors are not sup-
pressed.
RGM co-receptors are required for significant BMP 
signaling but not TGFβ signaling
Using the established C2C12 murine myoblast cell line
[30,31], targeted knockdown using siRNA duplexes of
each RGM co-receptor was performed to examine whether
they participate in BMP or TGFβ signaling.
Two independent readouts were used to determine BMP
responsiveness, a BMP-inducible luciferase reporter (BRE-
luc) and endogenous alkaline phosphatase (ALP) activity.
The reporter assay monitors signaling mediated by the
BMP-specific Smads [32], while ALP is an enzyme that is
upregulated in C2C12 cells in response to BMP but not
TGFβ treatment. In addition, TGFβ responsiveness was
assessed using the CAGA-luciferase reporter (CAGA-luc),
as this has been shown to monitor TGFβ signaling medi-
ated by smad3 [33]. Cells co-transfected with reporter
plasmids and siRNA duplexes were treated with BMP2
(100 ng/mL), BMP12 (10 μg/mL), or TGFβ (0.5 ng/mL).
The appropriate dose for each inducer was determined by
performing a dose-response curve using the relevant
reporter. While C2C12 cells are responsive to both BMP2
and BMP12, a much higher dose of the latter is required
to induce a response.Journal of Molecular Signaling 2007, 2:4 http://www.jmolecularsignaling.com/content/2/1/4
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Selective knockdown of RGMa, RGMb, or RGMc results in
dramatic loss of BMP2 and BMP12 responses in both the
BRE-luc and ALP activity assays (Figure 2). To further val-
idate the results shown in Figure 2, we tested the effect of
RGM knockdown in the BRE-luc assay over a wide range
of BMP2 concentrations. Our results (Figure 3) clearly
demonstrate that inhibition of RGM expression blocks
reporter activity over a wide range of BMP2 concentra-
tions. Compared to RGMa and RGMc, suppression of
RGMb mRNA shows a less dramatic, but still significant,
decrease in BMP activity. It should be noted that the sup-
pressive effects of RGM knockdown are not as strong in
the ALP assay, likely owing to the fact that the assay takes
place several days after the initial siRNA transfection, in
which case the RGM levels are likely starting to recover in
the cells. TGFβ response, however, was unaffected by the
absence of each individual RGM co-receptor (Figure 4).
The TGFβ type II receptor (TGFβR2) was knocked down as
a positive control, resulting in almost complete loss of cell
responsiveness to TGFβ treatment. The lack of a role for
the RGMs in the TGFβ pathway is consistent with previous
findings in which the RGMs were shown to enhance BMP
but not TGFβ signaling [19,20,22].
RGM co-receptors bind tightly to BMP2 and BMP12
Previous studies have shown qualitatively that RGMa,
RGMb, and RGMc interact with BMP proteins [19,20,22].
In order to more quantitatively evaluate the binding inter-
actions between the RGM co-receptors and BMP proteins,
binding kinetics and affinities were measured on Biacore
sensor chips. Purified RGM co-receptors were individually
flowed at a range of concentrations over immobilized
BMP2 and BMP12, followed by global analysis of each
data set. Biacore analysis demonstrates very tight binding
interactions between the RGM co-receptors and the BMP
proteins (Table 1) [also see Additional file 1]; all observed
interactions displayed kD's in the low nanomolar range.
This binding data indicates that the RGM co-receptors
likely bind to the BMP ligands on the cell surface, where
the RGMs are expressed.
Transient transfection of RGM co-receptors increases 
BMP signaling
In the presence of 14 ng/mL BMP2, transient overexpres-
sion of RGMa or RGMc increases BMP signaling com-
pared to the empty vector control (Figure 5). Co-
transfection of an equivalent total amount of RGMa/
RGMc further increased the BMP response in C2C12 cells,
demonstrating that BMP2 can more effectively signal
using a combination of two distinct RGM co-receptors
than using the same amount of a single RGM. RGMa and
RGMc were chosen since their knockdown most effec-
tively suppressed BMP signaling in the BMP activity
assays.
Discussion
Originally discovered as cell surface proteins with key
developmental roles in the nervous system, recent data
have confirmed a role for the RGM family in BMP signal-
ing. Due to the many and varied functions of TGFβ super-
family ligands, multiple levels of regulation are required
to tightly control cytokine function. In the BMP signaling
Relative RNA levels for each RGM after siRNA mediated knockdown Figure 1
Relative RNA levels for each RGM after siRNA mediated knockdown. Real-time quantitative Taqman RT-PCR analy-
sis was performed to test the effectiveness and specificity of RNA target knockdown in cells transfected with siRNA duplexes. 
A scramble control was tested in addition to four distinct siRNA duplexes that target RGMa (A), RGMb (B), or RGMc (C). 
Error bars represent the standard deviation (n = 4).
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Cell-based BMP activity assays Figure 2
Cell-based BMP activity assays. Cells in which RGMa (A), RGMb (B), or RGMc (C) levels were knocked down were 
treated with either BMP2 or BMP12 and assayed for ALP activity or BRE-luc activity. In each case, data from two effective 
siRNA duplexes are shown compared to the scramble siRNA sequence. In all cases, activities resulting from BMP2 or BMP12 
treatment are normalized to the activity of untreated cells. Error bars represent the standard deviation (n = 4). In all cases, the 
BMP-induced response from the RGM siRNA-treated cells was significantly lower than for the scramble siRNA-treated cells, as 
determined by a two-tailed Student's T-test (p-value threshold of 0.05).
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pathway, a primary regulatory mechanism is modulation
of ligand availability for its receptors. Preventing the
BMP/receptor interaction is accomplished by a host of
means, including extracellular BMP antagonists, receptor
expression, and the presence of BMP pseudoreceptors. In
contrast to these inhibitory mechanisms, the recent iden-
tification of the RGMs as BMP co-receptors offers a mech-
anism for enhancement of BMP signaling. Co-receptors,
or accessory receptors, have been similarly involved in sig-
naling for several other TGFβ superfamily members:
Cripto has been shown to be essential for BMP16/Nodal
signaling [18,34], TGFβ type III receptor (also called
betaglycan) is involved in TGFβ2 signaling [35], and
endoglin has been implicated as an accessory protein in
multiple TGFβ superfamily receptor complexes [36].
To better define the roles of the RGMs as co-receptors in
BMP signaling, cellular mRNA for each RGM was knocked
down via RNAi in cell culture and BMP responsiveness
was examined. Additionally, TGFβ responsiveness was
examined with the same approach. Interestingly, both
BMP activity assays (BRE-luc and ALP enzyme activity)
show that loss of either RGMa or RGMc dramatically
decreases BMP2 and BMP12 responsiveness. The loss of
RGMb has a more modest effect, though still significant.
The same results were observed in RGM knockdown
experiments that were carried out over a range of BMP2
concentrations (Figure 3). Although it has been shown
that BMP12 can signal through the BMP2 pathway [29],
the high dose needed to stimulate a BMP12 response in
our experimental system suggests that we may be forcing
BMP12 to use this pathway. It is possible that lower doses
of BMP12 may be able to signal through an as-yet unchar-
acterized signaling pathway, and the role of the RGMs in
this hypothetical pathway are unknown.
To be sure the observed effects were a result of specific
RNA degradation, and not off-target effects mediated by
the siRNA duplexes, individual experiments were carried
out using four unique siRNA nucleotide sequence targets
for each RGM co-receptor. Knockdown of RGMa, RGMb,
and RGMc was successfully accomplished by each of the
four siRNA duplexes targeting the proteins. Additionally,
the observed assay results were virtually identical regard-
less of which of the four sequences was used to suppress
mRNA levels (data not shown). As a negative control, ON-
TARGET  plus  si  CONTROL  non-targeting pool siRNA
duplexes (i.e., "scramble") were transfected in parallel
with the RGM-targeting siRNA reagents. Taken together,
the data indicate that all 3 coreceptors play roles in poten-
tiating BMP signaling, as knockdown of each significantly
reduces BMP response in cell culture.
BMP2 induced BRE-luc activity over a dose range Figure 3
BMP2 induced BRE-luc activity over a dose range. RNA knockdown of the indicated target was performed over a range 
of BMP2 concentrations in C2C12 cells. Error bars represent the standard deviation (n = 4).
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Previous studies have shown that transient over-expres-
sion of RGMa, RGMb, or RGMc significantly increases the
sensitivity of BMP-responsive cells in culture [20-22].
Additionally, we observe that transient transfection of
each RGM-Fc fusion protein in cell culture shows a repres-
sion of BMP activity (data not shown), demonstrating
that the soluble forms of these co-receptors are capable of
binding to and antagonizing BMP when not bound to the
cell membrane.
Given their critical role in BMP signaling, experiments
were carried out with the aim of quantifying the interac-
tions between the RGM co-receptors and BMP2 or
BMP12. The RGMs have been observed to bind qualita-
tively to BMP proteins previously, with a published equi-
librium dissociation rate constant (kD) only for the
RGMb:BMP2 interaction [19]. We therefore sought to
quantitatively analyze the binding of BMP2 and BMP12
to each RGM protein using a Biacore platform. The bind-
ing results show that all three RGM proteins bind with
very high affinity (equilibrium dissociation constants, kD,
in the low nanomolar range) to both BMP2 and BMP12.
These tight affinities further confirm the observations that
each RGM protein is capable of binding directly to the
BMP ligands. This suggests that in their native GPI-bound
form on the cell membrane, the RGM co-receptors are
able to directly bind the BMP ligands; it is possible that
this direct binding may lead to enhanced cytokine recruit-
ment to the type I/II receptor complexes.
Perhaps the most interesting data from our studies is evi-
dence that the RGM co-receptors are not able to compen-
sate functionally for one another. All 3 RGMs are
expressed in our cell system, C2C12; if the RGMs have
redundant activities, knocking down levels of one co-
receptor would not lead to a significant phenotypic result
due to the presence of the other two. In such a case, knock-
down of all three receptors would be needed before the
signaling pathways are affected. However, our data show
that reduced expression of a single RGM protein sup-
presses BMP activity in cells. The collective data suggest a
mechanism in which the signaling BMP receptor complex
requires two distinct RGM co-receptors for efficient sign-
aling, though it is unclear whether they exist as a het-
erodimer or two distinct proteins. In this model, the
possibilities are RGMa/RGMb, RGMa/RGMc, or RGMb/
RGMc. In our cell system, RGMa/RGMc is the most effec-
tive combination, as suppression of either one signifi-
cantly blocks BMP activity. Since knockdown of RGMb
has the least significant effect, this suggests that complexes
involving RGMb form less effective signaling complexes.
Previous studies have shown that the RGM proteins have
the ability to participate in BMP-receptor complexes.
Thus, it appears that the presence of two RGM proteins
Cell-based TGFβ activity assay Figure 4
Cell-based TGFβ activity assay. Cells in which RGMa, 
RGMb, or RGMc levels were knocked down were treated 
with TGFβ and assayed for CAGA-luc activity. Knockdown 
of TGFβ RII was also performed as a positive control. Error 
bars represent the standard deviation (n = 4). The TGFβ-
induced response from the RGM and scramble siRNA-
treated cells showed no significant difference from each 
other, while the TGFβ R2 siRNA-treated cells showed signif-
icantly lower responsiveness, as determined by a two-tailed 
Student's T-test (p value threshold of 0.05).
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Table 1: Kinetic analysis of BMP2 and BMP12 binding interactions with the RGM coreceptors
BMP2 Kon (M-1s-1)K off (s-1)K D(nM)
RGMa 1.48 × 105 3.64 × 10-4 2.46
RGMb 4.72 × 104 2.56 × 10-4 5.43
RGMc 8.61 × 104 3.63 × 10-4 4.22
BMP12 Kon (M-1s-1)K off (s-1)K D(nM)
RGMa 1.27 × 105 1.79 × 10-4 1.41
RGMb 5.69 × 104 1.18 × 10-4 2.06
RGMc 7.56 × 104 9.22 × 10-5 1.22
BIAevaluation software was used to analyze the binding kinetics of BMP2 or BMP12 binding to each RGM co-receptor. In all cases, kinetic 
parameters were obtained from global analysis of protein binding kinetics [see Additional file 1 for binding curves]Journal of Molecular Signaling 2007, 2:4 http://www.jmolecularsignaling.com/content/2/1/4
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enhances BMP ligand recruitment to the membrane-
bound receptors, and helps generate an active signaling
complex. Our data indicate that RGMa and RGMc form
the most potent co-receptor pair in the context of our in
vitro  cell system. In accord with previous results, we
observe no involvement of the RGM proteins in TGFβ sig-
naling.
According to our proposed mechanism, in which the
RGMa/RGMc combination of co-receptors is most potent
at facilitating BMP signaling, cells that overexpress this
combination should show improved BMP signaling ver-
sus cells that overexpress RGMa or RGMc individually.
Experiments in which cells are transiently transfected with
the same total amount of empty vector, RGMa, RGMc, or
a RGMa/RGMc combination show a statistically signifi-
cant (p value < 0.05, n = 4) increase in BMP activity (BRE-
luc readout) when the RGMa/RGMc combination of co-
receptors is expressed versus RGMa or RGMc individually.
Overexpression of RGMa or RGMc individually also
increase BMP signaling versus empty vector controls, con-
sistent with previously published data [19,20,22].
In addition to our cell-based assay data, several lines of
evidence support our proposed mechanism. Analysis of
endogenous RNA expression levels in a variety of BMP
responsive cell lines (C2C12, C3H10 T 1/2, 3T3L1, and
MLB13MYC Clone 14) shows that RGMa and RGMb RNA
is abundant in each cell line, while RGMc RNA is appreci-
ably expressed in C2C12 and MLB13MYC Clone 14 (data
not shown). This expression data supports the hypothesis
that two of the RGM co-receptors are needed for effective
BMP signaling, since all tested BMP-responsive cell lines
express at least two of the RGM proteins. Also, there is evi-
dence that the RGM proteins do not functionally compen-
sate for one another. It has been shown that mutations to
the gene encoding RGMc are a leading cause of juvenile
hemochromatosis, presumably due to loss of functional
RGMc protein. The fact that RGMa and RGMb do not res-
cue this disease phenotype (when caused by mutated
RGMc) suggests that they are not functionally redundant
with RGMc protein. While all these results support our
proposed mechanism, further experiments are required to
more fully elucidate it. Alternatively, other explanations
are possible. For example, the RGMs may act as mono-
meric coreceptors that can operate by different signaling
routes; these pathways may be functionally distinct in cer-
tain BMP-induced activities (such as those measured in
our experiments) but not in others. Additional studies are
required to fully understand the mechanisms through
which the RGMs regulate BMP signaling.
Conclusion
Our results build upon previous studies that have demon-
strated that each RGM protein serves as a BMP co-receptor.
It is clear that not only does the presence of these co-recep-
tors potentiate BMP signaling, but also that their absence
diminishes BMP responsiveness in vitro. Thus, the RGM
co-receptors are necessary for significant signaling
through the BMP, but not the TGFβ, pathway. Based on
our results, a pair of RGM co-receptors is minimally
required to form an effective signaling complex, though
the details of this process are still unclear.
Methods
Reagents and Proteins
Human BMP2 was produced and purified as previously
described [37]. Human BMP12 was produced in E.coli and
purified through a series of SP-Sepharose cation exchange
column steps, with final purification achieved by size
exclusion chromatography on two tandem TOSOH
G3000SWL columns. The BMP12 dimer peak from the
size exclusion column was dialyzed to 0.1% TFA followed
by concentration on a ThermoSavant SPD SpeedVac.
TGFβ-1 protein was purchased from R&D Systems.
RGM overexpression in C2C12 cells Figure 5
RGM overexpression in C2C12 cells. Cells were tran-
siently transfected with the same total amount of either 
empty vector, RGMa, RGMc, or RGMa/RGMc, followed by 
BMP2 treatment, and then assayed for BRE-luc activity. Error 
bars represent the standard deviation (n = 4). Significantly 
higher BRE-luc activity was observed in cells co-transfected 
with RGMa/RGMc than in cells transfected in either RGMa 
or RGMc alone, as determined by a two-tailed Student's T-
test (p value threshold of 0.05). Cells transfected without co-
receptors (empty vector) showed significantly lower BRE-luc 
activity than all other treatments.
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Receptor-Fc production and purification
RGMa-Fc, RGMb-Fc, and RGMc-Fc were produced in Free-
Style 293-F cells (Invitrogen) transiently transfected with
expression plasmids encoding the ectodomain of each
RGM fused to the Fc portion of human immunoglobulin
(IgG) to generate soluble fusion protein. Transfections
were performed with 293Fectin (Invitrogen) in serum-free
medium according to the manufacturer's instructions. For
each Fc-fusion protein, ~40 mL of conditioned medium
was centrifuged, filtered, and diluted 4-fold in 20 mM
sodium phosphate (pH 7.0) before one-step purification
on a Protein G affinity column (HiTrap Protein G HP,
Amersham Biosciences). After elution in 0.1 M glycine
(pH 2.7) and addition of Tris-HCl (pH 9.0) to neutralize
pH, the protein was concentrated and the buffer
exchanged using a Centricon centrifugal filter device (Mil-
lipore). Purified RGM-Fc's were analyzed using SDS-
PAGE; to confirm purity, gels were either blue stained or
transferred to a nitrocellulose membrane and Western
blotted using α-human IgG polyclonal antibodies.
BMP and TGFβ activity assays in C2C12 cells
C2C12 cells [30,31] were transiently transfected in 6-well
plates using Lipofectamine 2000 (Invitrogen) with a BMP
responsive firefly luciferase reporter (BRE-luc [32]) or a
TGFβ responsive firefly luciferase reporter (CAGA-luc
[33]) with pRL-TK Renilla luciferase vector to control for
transfection efficiency, in combination with the si
GENOME  ON-TARGET  plus  siRNA duplexes (Dhar-
macon) targeting a specific co-receptor, receptor
(TGFβR2), or scramble sequence. Dharmacon catalog
numbers for these reagents are LU-055474-00-0002
(RGMa), LU-055534-00-0002 (RGMb), LU-055494-00-
0002 (RGMc), LU-040618-00-0002 (TGFβR2), and D-
001210-01-05 (scramble sequence). After 24 hours, the
cells were trypsinized, harvested, and either reseeded into
96-well plates or used for RNA extraction (see below).
Reseeded cells were treated with purified ligand (100 ng/
mL BMP2, 10 μg/mL BMP12, or 0.5 ng/mL TGFβ) in
DMEM supplemented with 1% FBS and assayed for either
luciferase activity (after 24 hours) or alkaline phosphatase
(ALP) activity (after 4 days). Luciferase activity was deter-
mined after cell lysis using the Dual-Glo Luciferase Assay
System (Promega), and all experiments were performed in
quadruplicate wells. In all cases, firefly luciferase levels
were normalized to the corresponding amount of Renilla
luciferase in a given well, yielding the final values in rela-
tive luciferase units. ALP activity assays were performed as
described previously [38]. Briefly, following cell wash and
lysis, ALP activity of the cell lysates was tested in assay
buffer (0.1 M glycine, 8 mM MgCl2, and 0.1% Triton X-
100) using 10 mM p-nitrophenyl phosphate as a substrate
at 37°C. ALP activity was normalized to DNA levels in
each well to account for potential differences in cell
number.
Quantitative Real-Time PCR analysis of Receptor 
Expression
Messenger RNA was extracted and purified from the tran-
siently transfected C2C12 cells after 24 hours using the
RNeasy mini kit (Qiagen, Valencia, CA), including an on-
column DNAse I treatment step to digest any contaminat-
ing genomic DNA. Real-time quantitative RT-PCR was
performed in a one-step procedure combining cDNA syn-
thesis with PCR amplification on an ABI Prism 7900 HT
Fast Real-Time PCR system (Applied Biosystems).
Sequence specific primers and FAM-labelled probes used
for individual genes were also obtained from Applied Bio-
systems, catalog numbers Mm00624998_m1 (RGMa),
Mm00724273_m1 (RGMb) and Mm01265683_m1
(RGMc). The RT step involved incubation at 48°C for 30
min, followed by the PCR cycling conditions (initial
denaturation of 95°C for 10 min, followed by 40 cycles of
95°C for 15 seconds and 60°C for 1 minute) in 96-well
plates. For each reaction, the cycle threshold (Ct) was
determined as the cycle number at which a threshold flu-
orescence value (set in the exponential phase of the ampli-
fication curves) was reached. In order to measure reaction
efficiency, a standard curve was generated using 100, 20,
4, 0.8, and 0.16 ng of total starting RNA. In all cases, gene
expression levels were normalized to GAPDH expression
levels in order to assess changes in relative expression.
Binding analysis using surface plasmon resonance 
(Biacore)
Binding experiments and kinetics analyses were per-
formed using the BIAcore 3000 (Biacore), the basic prin-
ciples of which are well documented [39,40]. Purified
recombinant human BMP2 or BMP12 were prepared in
immobilization buffer (10 mM Acetate, pH 4.5) at a con-
centration of 10 ug/mL and were immobilized on sensor
chips (CM5, research grade, Biacore) by the amine cou-
pling method at a flow rate of 10 ul/min at 25°C. The
immobilization levels for BMP2 and BMP12 were 350
and 1000 RUs, respectively. For binding analysis, soluble
receptor (RGMa, RGMb, or RGMc) was injected over a
range of concentrations between 0.1 nM to 100 nM at
25°C at a flow rate of 30 uL/min for 500 s. The resulting
data from multiple experiments were globally analyzed
using BIAevaluation software version 3.2 (Biacore) to
determine kinetic parameters, association rate constant
(ka), and dissociation rate constant (kd). Degassed HBS-
EP (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, and
0.005% Nonidet P-40, pH 7.4) was used as running buffer
and for sample dilution. Surface regeneration after ligand
binding was efficiently accomplished by injection of 100
mM HCl (20 uL), as determined by preliminary experi-
ments. In all cases, double referencing [41] was performed
to correct for any non-specific binding or buffer related
artifacts.Journal of Molecular Signaling 2007, 2:4 http://www.jmolecularsignaling.com/content/2/1/4
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Overexpression of RGM proteins in C2C12 cells
C2C12 cells were transiently transfected in 96-well plates
with an empty vector control, RGMa, RGMc, or a combi-
nation of 1:1 RGMa/RGMc. In all cases, the same total
amount of expression plasmid was transfected into each
well. Simultaneous co-transfection of the BRE-luc and
pRL-TK Renilla reporters was performed as above. In ini-
tial experiments, Cells were treated with 100 ng/ml of
BMP2 for 24 hours and BRE-luc activity was assayed as
described above. Subsequent experiments found that a
lower dose of BMP2 (14 ng/ml) was more effective.
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